Spinning molecular immunology into successful immunotherapy (original) (raw)

• Haywood, G. R. & McKhann, C. F. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J. Exp. Med. 133, 1171–1187 (1971).
  CAS PubMed PubMed Central Google Scholar
• Hui, K., Grosveld, F. & Festenstein, H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311, 750–752 (1984).
  CAS PubMed Google Scholar
• Travers, P. J., Arklie, J. L., Trowsdale, J., Patillo, R. A. & Bodmer, W. F. Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines. Natl Cancer Inst. Monogr. 60, 175–180 (1982).
  CAS PubMed Google Scholar
• Kaklamanis, L. et al. Loss of HLA class-I alleles, heavy chains and β2-microglobulin in colorectal cancer. Int. J. Cancer 51, 379–385 (1992).
  CAS PubMed Google Scholar
• Restifo, N. P. et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265–272 (1993).
  CAS PubMed Google Scholar
• Torre, A. G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl Acad. Sci. USA 87, 1486–1490 (1990).
  Google Scholar
• Bogen, B. Peripheral T-cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26, 2671–2679 (1996).
  CAS PubMed Google Scholar
• Speiser, D. E. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645–653 (1997).
  CAS PubMed PubMed Central Google Scholar
• Staveley-O'Carroll, K. et al. Induction of antigen-specific T-cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178–1183 (1998).
  CAS PubMed PubMed Central Google Scholar
• Wick, M. et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T-cell exhaustion or systemic anergy. J. Exp. Med. 186, 229–238 (1997).
  CAS PubMed PubMed Central Google Scholar
• Hung, K. et al. The central role of CD4+ T cells in the anti-tumor immune response. J. Exp. Med. 188, 2357–2368 (1998).
  CAS PubMed PubMed Central Google Scholar
• Qin, Z. et al. B cells inhibit induction of T-cell-dependent tumor immunity. Nature Med. 4, 627–630 (1998).
  CAS PubMed Google Scholar
• Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136 (1990).
  CAS PubMed Google Scholar
• Munger, K. et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099–4105 (1989).
  CAS PubMed PubMed Central Google Scholar
• Galloway, D. A. & Jenison, S. A. Characterization of the humoral immune response to genital papillomaviruses. Mol. Biol. Med. 7, 59–72 (1990).
  CAS PubMed Google Scholar
• Howley, P. M. in Fundamental Virology (eds Fields, B. N. & Knipe, D. M.) 743–763 (Raven, New York, 1991).
  Google Scholar
• Beasley, R. P., Hwang, L. Y., Lin, C. C. & Chien, C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2, 1129–1133 (1981).
  CAS PubMed Google Scholar
• Brechot, C. What is the role of hepatitis B virus in the appearance of hepatocellular carcinomas in patients with alcoholic cirrhosis? Gastroenterol. Clin. Biol. 6, 727–730 (1982).
  CAS PubMed Google Scholar
• Szmuness, W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a casual association. Prog. Med. Virol. 24, 40–69 (1978).
  CAS PubMed Google Scholar
• Shafritz, D. A., Shouval, D., Sherman, H. I., Hadziyannis, S. J. & Kew, M. C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N. Engl. J. Med. 305, 1067–1073 (1981).
  CAS PubMed Google Scholar
• zur Hausen, H., Schulte-Holthausen, H. & Klein, G. EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature 228, 1056–1059 (1970).
  CAS PubMed Google Scholar
• Weiss, L. M., Movahed, L. A., Warnke, R. A. & Sklar, J. Detection of Epstein–Barr viral genomes in Reed–Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 320, 502–506 (1989).
  CAS PubMed Google Scholar
• Wu, T. C. et al. Detection of EBV gene expression in Reed–Sternberg cells of Hodgkin's disease. Int. J. Cancer 46, 801–804 (1990).
  CAS PubMed Google Scholar
• Steinman, R. M. The dendritic-cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296 (1991).
  CAS PubMed Google Scholar
• Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
  Article CAS PubMed Google Scholar
• Inaba, K. et al. Identification of proliferating dendritic-cell precursors in mouse blood. J. Exp. Med. 175, 1157–1167 (1992).
  CAS PubMed Google Scholar
• Caux, C., Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261 (1992).
  CAS PubMed Google Scholar
• Kiertscher, S. M. & Roth, M. D. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukocyte Biol. 59, 208–218 (1996).
  CAS PubMed Google Scholar
• Romani, N. R. D. et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137–151 (1996).
  CAS PubMed Google Scholar
• Maraskovsky, E. et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3-ligand-treated mice: multiple dendritic-cell subpopulations identified. J. Exp. Med. 184, 1953–1962 (1996).
  CAS PubMed Google Scholar
• Akira, S. T. K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2, 675–680 (2001).
  CAS Google Scholar
• Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109–1118 (1994).
  CAS PubMed Google Scholar
• Caux, C. et al. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180, 1263–1272 (1994).
  CAS PubMed Google Scholar
• Cella, M. et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T–T help via APC activation. J. Exp. Med. 184, 747–752 (1996).
  CAS PubMed Google Scholar
• Cella, M., Engering, A., Pinet, V., Pieters, J. & Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782–787 (1997).
  CAS PubMed Google Scholar
• Pierre, P. et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388, 787–792 (1997).
  CAS PubMed Google Scholar
• Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).Comprehensive comparison of the relative efficacies of whole-cell tumour vaccines engineered to secrete a panel of different cytokines. This study identified GM-CSF-transduced tumour vaccines as uniquely generating potent systemic antitumour immunity and provided an in vivo correlate to the studies that showed the role of GM-CSF in the induction of DC differentiation.
  CAS PubMed PubMed Central Google Scholar
• Pardoll, D. M. & Jaffee, E. M. in Principles and Practice of Biologic Therapy of Cancer (Silverchair, Charlottesville, 1999).
  Google Scholar
• Chiodoni, C. et al. Dendritic cells infiltrating tumors cotransduced with granulocyte–macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T-lymphocyte response. J. Exp. Med. 190, 125–133 (1999).Demonstration of the enhanced effectiveness of engineered tumour-cell vaccines that secrete a combination of DC mitogen (GM-CSF) and activation (CD40L) factors in locally activating DCs and producing systemic antitumour immunity.
  CAS PubMed PubMed Central Google Scholar
• Tao, M. H. & Levy, R. Idiotype/granulocyte–macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755–758 (1993).
  CAS PubMed Google Scholar
• Small, E. J. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894–3903 (2000).
  CAS PubMed Google Scholar
• Tendler, D. S. et al. Intersection of interferon and hypoxia signal-transduction pathways in nitric-oxide-induced tumor apoptosis. Cancer Res. 61, 3682–3688 (2001).
  CAS PubMed Google Scholar
• Simons, J. W. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537–1546 (1997).
  CAS PubMed PubMed Central Google Scholar
• Soiffer, R. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 95, 13141–13146 (1998).
  CAS PubMed PubMed Central Google Scholar
• Jaffee, E. M. et al. Novel allogeneic granulocyte–macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145–156 (2001).
  CAS PubMed Google Scholar
• Porgador, A. & Gilboa, E. Bone-marrow-generated dendritic cells pulsed with a class-I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182, 255–260 (1995).
  CAS PubMed Google Scholar
• Mayordomo, J. I. et al. Bone-marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297–1302 (1995).
  CAS PubMed Google Scholar
• Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor-lysate-pulsed dendritic cells. Nature Med. 4, 328–332 (1998).
  CAS PubMed Google Scholar
• Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
  CAS PubMed Google Scholar
• Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317–322 (1996).
  CAS PubMed Google Scholar
• Lambert, L. A., Gibson, G. R., Maloney, M. & Barth, R. J. Jr. Equipotent generation of protective antitumor immunity by various methods of dendritic-cell loading with whole cell tumor antigens. J. Immunother. 24, 232–236 (2001).
  CAS PubMed Google Scholar
• Shimizu, K., Thomas, E. K., Giedlin, M. & Mule, J. J. Enhancement of tumor lysate- and peptide-pulsed dendritic-cell-based vaccines by the addition of foreign helper protein. Cancer Res. 61, 2618–2624 (2001).
  CAS PubMed Google Scholar
• Song, W. et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247–1256 (1997).
  CAS PubMed PubMed Central Google Scholar
• Specht, J. M. et al. Dendritic cells retrovirally transduced with a model tumor antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213–1221 (1997).
  CAS PubMed PubMed Central Google Scholar
• Dyall, J., Latouche, J. B., Schnell, S. & Sadelain, M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97, 114–121 (2001).
  CAS PubMed Google Scholar
• Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465–472 (1996).
  CAS PubMed Google Scholar
• Reddy, A., Sapp, M., Feldman, M., Subklewe, M. & Bhardwaj, N. A monocyte-conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90, 3640–3646 (1997).
  CAS PubMed Google Scholar
• Bender, A. S. M., Schuler, G., Steinman, R. M. & Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196, 121–135 (1996).
  CAS PubMed Google Scholar
• Klein, C., Bueler, H. & Mulligan, R. C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191, 1699–1708 (2000).
  CAS PubMed PubMed Central Google Scholar
• Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3, 558–561 (1997).
  CAS PubMed Google Scholar
• Boyle, J. S., Brady, J. L. & Lew, A. M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392, 408–411 (1998).
  CAS PubMed Google Scholar
• You, Z., Huang, X., Hester, J., Toh, H. C. & Chen, S. Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61, 3704–3711 (2001).
  CAS PubMed Google Scholar
• Mahnke, K. et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151, 673–684 (2000).
  CAS PubMed PubMed Central Google Scholar
• Srivastava, P. K. Roles of heat-shock proteins in innate and adaptive immunity. Nature Rev. Immunol. 2, 185–194 (2002).
  CAS Google Scholar
• Tamura, Y., Peng, P., Liu, K., Daou, M. & Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat-shock protein preparations. Science 278, 117–120 (1997).
  CAS PubMed Google Scholar
• Udono, H. & Srivastava, P. K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90 and hsp70. J. Immunol. 152, 5398–5403 (1994).
  CAS PubMed Google Scholar
• Arnold, D., Faath, S., Rammensee, H. & Schild, H. Cross-priming of minor histocompatibity antigen-specific cytotoxic T cells upon immunization with the heat-shock protein gp96. J. Exp. Med. 182, 885–889 (1995).
  CAS PubMed Google Scholar
• Wang, X. Y., Kazim, L., Repasky, E. A. & Subjeck, J. R. Characterization of heat-shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166, 490–497 (2001).
  CAS PubMed Google Scholar
• Suzue, K., Zhou, X., Eisen, H. N. & Young, R. A. Heat-shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl Acad. Sci. USA 94, 13146–13151 (1997).
  CAS PubMed PubMed Central Google Scholar
• Castellino, F. et al. Receptor-mediated uptake of antigen/heat-shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med. 191, 1957–1964 (2000).
  CAS PubMed PubMed Central Google Scholar
• Chen, C. H. et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035–1042 (2000).References 65–71 indicate the different ways that various heat-shock proteins have been used to enhance tumour vaccine potency.
  CAS PubMed Google Scholar
• Suto, R. & Srivastava, P. K. A mechanism for the specific immunogenicity of heat-shock-protein-chaperoned peptides. Science 269, 1585–1588 (1995).
  CAS PubMed Google Scholar
• Basu, S., Binder, R. J., Ramalingam, T. & Srivastava, P. K. CD91 is a common receptor for heat-shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity 14, 303–313 (2001).
  CAS PubMed Google Scholar
• Asea, A. et al. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nature Med. 6, 435–442 (2000).Shows the ability of heat-shock proteins to act as activation signals for antigen-presenting cells.
  CAS PubMed Google Scholar
• Kuppner, M. C. et al. The role of heat-shock protein (hsp70) in dendritic-cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur. J. Immunol. 31, 1602–1609 (2001).
  CAS PubMed Google Scholar
• Boniface, J. J. & Davis, M. M. T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Ann. NY Acad. Sci. 766, 62–69 (1995).
  CAS PubMed Google Scholar
• Boon, T. O. L. Cancer tumor antigens. Curr. Opin. Immunol. 9, 681–683 (1997).
  CAS PubMed Google Scholar
• Robbins, P. F. & Kawakami, Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8, 628–636 (1996).
  CAS PubMed Google Scholar
• Parkhurst, M. R. et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157, 2539–2548 (1996).
  CAS PubMed Google Scholar
• Dyall, R. et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188, 1553–1561 (1998).References 79 and 80 show that modification of MHC anchor residues in a tumour peptide antigen can significantly enhance MHC binding without disrupting recognition by T cells specific for the wild-type peptide. Anchor modification is now commonly used to enhance the efficacy of peptide vaccines.
  CAS PubMed PubMed Central Google Scholar
• Slansky, J. E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC–peptide–TCR complex. Immunity 13, 529–538 (2000).Shows that modification of residues in an antigenic peptide that increase TCR affinity can increase the stimulation of significant repertoires of T cells specific for the wild-type peptide.
  CAS PubMed Google Scholar
• Wu, T. C. et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl Acad. Sci. USA 92, 11671–11675 (1995).
  CAS PubMed PubMed Central Google Scholar
• Lin, K. Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21–26 (1996).
  CAS PubMed Google Scholar
• Ji, H. et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 10, 2727–2740 (1999).
  CAS PubMed Google Scholar
• Hung, C. F. et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J. Immunol. 166, 5733–5740 (2001).
  CAS PubMed Google Scholar
• Hung, C. F. et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61, 3698–3703 (2001).
  CAS PubMed Google Scholar
• Livingston, B. D. et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19, 4652–4660 (2001).
  CAS PubMed Google Scholar
• Townsend, S. E. & Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368–370 (1993).
  CAS PubMed Google Scholar
• Chen, L. et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093–1102 (1992).
  CAS PubMed Google Scholar
• Huang, A. Y., Bruce, A. T., Pardoll, D. M. & Levitsky, H. I. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769–776 (1996).
  CAS PubMed Google Scholar
• Kim, J. J. et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotechnol. 15, 641–646 (1997).
  CAS Google Scholar
• Agadjanyan, M. G. et al. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. J. Immunol. 162, 3417–3427 (1999).
  CAS PubMed Google Scholar
• Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682–685 (1997).
  CAS PubMed Google Scholar
• Weinberg, A. D. et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164, 2160–2169 (2000).
  CAS PubMed Google Scholar
• Bansal-Pakala, P., Jember, A. G. & Croft, M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nature Med. 7, 907–912 (2001).
  CAS PubMed Google Scholar
• Atkins, M. B. et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).
  CAS PubMed Google Scholar
• Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D. & Reisfeld, R. A. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80, 277–292 (1998).
  CAS PubMed Google Scholar
• Ahlers, J. D., Dunlop, N., Alling, D. W., Nara, P. L. & Berzofsky, J. A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte–macrophage colony-stimulating factor and TNF-α synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158, 3947–3958 (1997).
  CAS PubMed Google Scholar
• Smith, G. L., Murphy, B. R. & Moss, B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc. Natl Acad. Sci. USA 80, 7155–7159 (1983).
  CAS PubMed PubMed Central Google Scholar
• Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 80, 5364–5368 (1983).
  CAS PubMed PubMed Central Google Scholar
• Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc. Natl Acad. Sci. USA 93, 11341–11348 (1996).
  CAS PubMed PubMed Central Google Scholar
• Carroll, M. W. et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15, 387–394 (1997).
  CAS PubMed PubMed Central Google Scholar
• Paoletti, E., Taylor, J., Meignier, B., Meric, C. & Tartaglia, J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol. Stand. 84, 159–163 (1995).
  CAS PubMed Google Scholar
• Velders, M. P. et al. Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61, 7861–7867 (2001).
  CAS PubMed Google Scholar
• Elzey, B. D., Siemens, D. R., Ratliff, T. L. & Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842–849 (2001).
  CAS PubMed Google Scholar
• Gewurz, B. E., Gaudet, R., Tortorella, D., Wang, E. W. & Ploegh, H. L. Virus subversion of immunity: a structural perspective. Curr. Opin. Immunol. 13, 442–450 (2001).
  CAS PubMed Google Scholar
• Irvine, K. R. et al. Enhancing efficacy of recombinant anticancer vaccines with prime–boost regimens that use two different vectors. J. Natl Cancer Inst. 89, 1595–1601 (1997).
  CAS PubMed Google Scholar
• Ramshaw, I. A. & Ramsay, A. J. The prime–boost strategy: exciting prospects for improved vaccination. Immunol. Today 21, 163–165 (2000).
  CAS PubMed Google Scholar
• Pan, Z. K., Ikonomidis, G., Lazenby, A., Pardoll, D. M. & Paterson, Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med. 1, 471–477 (1995).
  CAS PubMed Google Scholar
• Thole, J. E. et al. Live bacterial delivery systems for development of mucosal vaccines. Curr. Opin. Mol. Ther. 2, 94–99 (2000).
  CAS PubMed Google Scholar
• Killeen, K., Spriggs, D. & Mekalanos, J. Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. Curr. Top. Microbiol. Immunol. 236, 237–254 (1999).
  CAS PubMed Google Scholar
• Ohara, N. & Yamada, T. Recombinant BCG vaccines. Vaccine 19, 4089–4098 (2001).
  CAS PubMed Google Scholar
• Shata, M. T., Stevceva, L., Agwale, S., Lewis, G. K. & Hone, D. M. Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today 6, 66–71 (2000).
  CAS PubMed Google Scholar
• Sizemore, D. R., Branstrom, A. A. & Sadoff, J. C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299–302 (1995).
  CAS PubMed Google Scholar
• Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765–775 (1997).
  CAS PubMed Google Scholar
• Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565–594 (2001).
  CAS PubMed Google Scholar
• van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM–CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999).
  CAS PubMed PubMed Central Google Scholar
• Hurwitz, A. A., Yu, T. F., Leach, D. R. & Allison, J. P. CTLA-4 blockade synergizes with tumor-derived granulocyte–macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95, 10067–10071 (1998).
  CAS PubMed PubMed Central Google Scholar
• Hurwitz, A. A. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60, 2444–2448 (2000).
  CAS PubMed Google Scholar
• Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365–1369 (1999).
  CAS PubMed Google Scholar
• Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
  CAS PubMed PubMed Central Google Scholar
• Tseng, S.-Y. et al. B7-DC, a new dendritic-cell molecule with unique costimulatory properties for T cells. J. Exp. Med. 193, 839–846 (2001).
  CAS PubMed PubMed Central Google Scholar
• Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. Nature Immunol. 2, 261–268 (2001).
  CAS Google Scholar
• Ibarra-Sanchez, M. J. et al. The T-cell protein tyrosine phosphatase. Semin. Immunol. 12, 379–386 (2000).
  CAS PubMed Google Scholar
• Irie-Sasaki, J. et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349–354 (2001).
  CAS PubMed Google Scholar
• Greenhalgh, C. J. & Hilton, D. J. Negative regulation of cytokine signaling. J. Leukocyte Biol. 70, 348–356 (2001).
  CAS PubMed Google Scholar
• Vang, T. et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T-cell receptor. J. Exp. Med. 193, 497–507 (2001).
  CAS PubMed PubMed Central Google Scholar
• Chiang, Y. J. et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403, 216–220 (2000).
  CAS PubMed Google Scholar
• Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211–216 (2000).
  CAS PubMed Google Scholar
• Sun, L. et al. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 8, 703–711 (1998).
  CAS PubMed Google Scholar
• Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810–11813 (1995).
  CAS PubMed PubMed Central Google Scholar
• Gure, A. O. et al. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 72, 965–971 (1997).
  CAS PubMed Google Scholar
• Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).A combination of a GM-CSF-transduced melanoma cell vaccine and anti-CTLA4 antibodies are used to show that in vivo CTLA4 blockade can amplify vaccine potency significantly. As in reference 27 , anti-melanoma activity correlated with induction of vitiligo.
  CAS PubMed Google Scholar
• Fossum, B. et al. A K-ras 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int. J. Cancer 58, 506–511 (1994).Clinical survey of melanoma patients treated with different immunotherapies, showing that virtually all patients who develop therapy-related vitiligo have partial or complete tumour regression.
  CAS PubMed Google Scholar
• Fossum, B. et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int. J. Cancer 56, 40–45 (1994).First application of expression cloning to identify a human tumour antigen. The MAGE family is an important set of shared tumour antigens selectively expressed in tumours and testes but not in other normal adult tissues.
  CAS PubMed Google Scholar
• Kwak, L. W., Young, H. A., Pennington, R. W. & Weeks, S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte–macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93, 10972–10977 (1996).
  CAS PubMed PubMed Central Google Scholar
• Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor-cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982–2987 (1999).
  CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. & White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81–84 (1996).
  CAS PubMed Google Scholar
• Van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991).
  CAS PubMed Google Scholar